Business Wire

AMCS unveils the AMCS Platform Summer ‘23 edition, the second release this year, delivering exciting new productivity features and a dynamic customer experience for environmental, transportation, waste, recycling and resource operators

10.7.2023 18:15:00 EEST | Business Wire | Press release

Share

AMCS, the world leading technology provider for the environmental, waste, recycling and environmental health and safety industries, today announced the global launch of the AMCS Platform 2023 Summer release. The release offers important new benefits and features, including:

  • Order-to-Cash Automation to simplify and accelerate cashflow – Newly streamlined and optimised processes enable operators to invoice faster and more easily, so they can get paid sooner, creating a better experience for both users and customers. A new cash collection management module provides automated credit control to collect all receivables.
  • Maximised Asset Utilisation – The new Equipment Inventory module optimises visibility and control over container assets by quickly identifying slow-moving containers, ensuring they’re available to meet market demand, and allowing operators to optimise sales and minimise the costs associated with the physical loss of containers.

    Significant enhancements to the Transport Solutions platform user experience will boost scheduling and maintenance productivity of both fleet owners and planners, empowering them to optimise utilisation of company fleet assets.
  • Digitalisation of Purchase to Pay – A streamlined process will allow recyclers to seamlessly manage tickets for the purchase of feedstock. Scrap recyclers can capture supplier data quickly and easily to ensure regulatory compliance. Integrated, flexible supplier payments allow cash (including ATM), check, and ACH, as well as exciting emerging digital instant payment types (using AMCS Pay) including push-to-debit and pre-paid cards. These connected, digitalised processes will automate, connect, and accelerate purchasing, compliance, scale, supplier payment, and financial tasks, boosting both efficiency and competitiveness.

“Our continued investment in automation processes is the major theme of the AMCS Platform. The Summer ’23 release delivers real business value,” says Elaine Treacy, Global Product Director at AMCS. Treacy continues, “Newly optimised ‘order to cash’ processes will drive faster payments with less effort, reducing the risk of overdue payments and bad debt. Our new streamlined ‘purchase to pay‘enables recyclers to purchase feedstock in an efficient and regulatory compliant manner. In addition to supplier settlements using cash and checks, we are introducing exciting digital payment options.”

The investment in enhanced user experiences and a new equipment inventory feature will allow AMCS customers to drive greater utilisation and financial return from their container and truck assets, and thus improve their sales. Other highlights of the summer release include:

  • Full integration of AMCS Vision AI into the AMCS Platform, providing new dashboards for insight as well as options to automatically charge for exceptions such as overfills and contamination.
  • A new Sustainability Dashboard on the AMCS Customer Portal, allowing customers to share key sustainability performance metrics with their end users.
  • New Customer Self-Serve features, including support for Interactive Voice Response (IVR) for PCI compliant payments and the digital exchange of Duty of Care (UK) compliance documentation.
  • For municipal operators, more streamlined invoice processing of direct residential subscribers and enhanced controls on the service status of customers, depending on their payment standing.
  • A new and improved AMCS Academy online customer training platform, with more compelling and engaging training experiences.

To learn more about AMCS Platform Summer ‘23 Release, visit www.amcsgroup.com

About AMCS Group

AMCS, with offices in Europe, North America and Australia is a global technology leader for the environmental, waste, recycling, and resource industries. We help over 4,000 customers reduce their operating costs, increase asset utilisation, optimise margins, drive sustainability, and improve customer service. Our enterprise software and SaaS solutions deliver digital innovation to the emerging circular economy around the world. Read more about AMCS at www.amcsgroup.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Austen Lees
Sirius Communications
austen@siriuscomms.co.uk
Tel.: 00447773813210

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye